Pharsight

Arnuity Ellipta patents expiration

ARNUITY ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(4 years from now)

US9333310

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2028

(4 years from now)

US8113199

(Pediatric)

GLAXOSMITHKLINE Counter for use with a medicament dispenser
Apr, 2028

(4 years from now)

US8161968

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Aug, 2028

(4 years from now)

US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8534281

(Pediatric)

GLAXOSMITHKLINE Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(7 years from now)

Arnuity Ellipta is owned by Glaxosmithkline.

Arnuity Ellipta contains Fluticasone Furoate.

Arnuity Ellipta has a total of 11 drug patents out of which 0 drug patents have expired.

Arnuity Ellipta was authorised for market use on 20 August, 2014.

Arnuity Ellipta is available in powder;inhalation dosage forms.

The generics of Arnuity Ellipta are possible to be released after 11 April, 2031.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Mar 1, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic